344 related articles for article (PubMed ID: 16918124)
21. Potential for molecular targeted therapy of HER-2/neu for invasive bladder cancer: examination of gene amplification by fluorescence in situ hybridization.
Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Hirano M; Hayashida K; Mizumukai E; Nanaura H; Honda N
Oncol Rep; 2007 Nov; 18(5):1183-7. PubMed ID: 17914570
[TBL] [Abstract][Full Text] [Related]
22. Potential for HER-2/neu molecular targeted therapy for invasive bladder carcinoma: comparative study of immunohistochemistry and fluorescent in situ hybridization.
Matsubara H; Yamada Y; Naruse K; Nakamura K; Aoki S; Taki T; Tobiume M; Zennami K; Katsuda R; Honda N
Oncol Rep; 2008 Jan; 19(1):57-63. PubMed ID: 18097576
[TBL] [Abstract][Full Text] [Related]
23. Molecular markers in bladder cancer: a critical appraisal.
Konety BR
Urol Oncol; 2006; 24(4):326-37. PubMed ID: 16818187
[TBL] [Abstract][Full Text] [Related]
24. Molecular biology of bladder cancer.
Borland RN; Brendler CB; Isaacs WB
Hematol Oncol Clin North Am; 1992 Feb; 6(1):31-9. PubMed ID: 1556051
[TBL] [Abstract][Full Text] [Related]
25. Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma.
Wang XS; Zhang Z; Wang HC; Cai JL; Xu QW; Li MQ; Chen YC; Qian XP; Lu TJ; Yu LZ; Zhang Y; Xin DQ; Na YQ; Chen WF
Clin Cancer Res; 2006 Aug; 12(16):4851-8. PubMed ID: 16914571
[TBL] [Abstract][Full Text] [Related]
26. Current understanding of the biology of advanced bladder cancer.
Al-Sukhun S; Hussain M
Cancer; 2003 Apr; 97(8 Suppl):2064-75. PubMed ID: 12673698
[TBL] [Abstract][Full Text] [Related]
27. Epigenetic biomarkers in urothelial bladder cancer.
Kim WJ; Kim YJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):259-69. PubMed ID: 19379084
[TBL] [Abstract][Full Text] [Related]
28. Molecular markers for detection, surveillance and prognostication of bladder cancer.
Vrooman OP; Witjes JA
Int J Urol; 2009 Mar; 16(3):234-43. PubMed ID: 19298346
[TBL] [Abstract][Full Text] [Related]
29. Transitional cell tumors of the ovary: a comparative clinicopathologic, immunohistochemical, and molecular genetic analysis of Brenner tumors and transitional cell carcinomas.
Cuatrecasas M; Catasus L; Palacios J; Prat J
Am J Surg Pathol; 2009 Apr; 33(4):556-67. PubMed ID: 19033864
[TBL] [Abstract][Full Text] [Related]
30. Bladder cancer: modeling and translation.
Rosenberg JE; Hahn WC
Genes Dev; 2009 Mar; 23(6):655-9. PubMed ID: 19299556
[TBL] [Abstract][Full Text] [Related]
31. Molecular cytogenetic characterization and diagnostics of bladder cancer.
Houskova L; Zemanova Z; Babjuk M; Melichercikova J; Pesl M; Michalova K
Neoplasma; 2007; 54(6):511-6. PubMed ID: 17949235
[TBL] [Abstract][Full Text] [Related]
32. Gene signatures for risk-adapted treatment of bladder cancer.
Ørntoft TF; Dyrskjøt L
Scand J Urol Nephrol Suppl; 2008 Sep; (218):166-74. PubMed ID: 18815931
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.
Wolff EM; Liang G; Jones PA
Nat Clin Pract Urol; 2005 Oct; 2(10):502-10. PubMed ID: 16474624
[TBL] [Abstract][Full Text] [Related]
34. Large-scale analysis of cell cycle regulators in urothelial bladder cancer identifies p16 and p27 as potentially useful prognostic markers.
Brunner A; Verdorfer I; Prelog M; Mayerl C; Mikuz G; Tzankov A
Pathobiology; 2008; 75(1):25-33. PubMed ID: 18334837
[TBL] [Abstract][Full Text] [Related]
35. Epigenetic markers as promising prognosticators for bladder cancer.
Kim YK; Kim WJ
Int J Urol; 2009 Jan; 16(1):17-22. PubMed ID: 18721202
[TBL] [Abstract][Full Text] [Related]
36. Urothelial cancer biomarkers for detection and surveillance.
Liou LS
Urology; 2006 Mar; 67(3 Suppl 1):25-33; discussion 33-4. PubMed ID: 16530072
[TBL] [Abstract][Full Text] [Related]
37. Molecular prognostic factors in adenocarcinoma of the esophagus and gastroesophageal junction.
Lagarde SM; ten Kate FJ; Richel DJ; Offerhaus GJ; van Lanschot JJ
Ann Surg Oncol; 2007 Feb; 14(2):977-91. PubMed ID: 17122988
[TBL] [Abstract][Full Text] [Related]
38. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
[TBL] [Abstract][Full Text] [Related]
39. p53 gene and protein status: the role of p53 alterations in predicting outcome in patients with bladder cancer.
George B; Datar RH; Wu L; Cai J; Patten N; Beil SJ; Groshen S; Stein J; Skinner D; Jones PA; Cote RJ
J Clin Oncol; 2007 Dec; 25(34):5352-8. PubMed ID: 18048815
[TBL] [Abstract][Full Text] [Related]
40. Genetic alterations in urothelial bladder carcinoma: an updated review.
Mhawech-Fauceglia P; Cheney RT; Schwaller J
Cancer; 2006 Mar; 106(6):1205-16. PubMed ID: 16470587
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
